Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Seeking Alpha6/25/2026Neutral
PASG
Passage Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.06M
P/E Ratio
—
EPS
$-12.54
Beta
1.42
52W High
$20.00
52W Low
$3.29
50-Day MA
$5.24
200-Day MA
$8.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Passage Bio Inc
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-37.55M |
| Operating Margin | 0.00% |
| Return on Equity | -128.90% |
| Return on Assets | -39.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.66 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.21M |
| Float | $2.89M |
| % Insiders | 7.72% |
| % Institutions | 59.85% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Analyst Ratings
Consensus ($15.50 target)
2
Buy3
HoldLatest News
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
GlobeNewsWire6/24/2026Neutral
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
GlobeNewsWire4/20/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026